# Zhongji Zhiyao (Nanjing) Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zhongji-zhiyao-nanjing-biotechnology-co

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Total disclosed funding: $17M
- Latest round: Series A (Feb 1, 2022)
- Investors on record: 4

## About

Based in Nanjing, China, and established in 2020, Zhongji Zhiyao (Nanjing) Biotechnology Co., Ltd. is a biotechnology company that focuses on the field of gene therapy. The company integrated R&D, production, and sales of gene therapy drugs. Moreover, the company's three founders have 20 years of experience in gene therapy and regulation of gene expression. The company's vice president is Dr. Yanjun Zhang, who graduated German National Cancer Research Center, and served in Chinese Academy of Medical Sciences, focusing on R&D of eukaryotic gene expression regulation. The company focuses on R&D of new drugs of single gene genetic diseases, including Recessive Dystrophic Epidermolysis Bullosa (RDEB) and ß-Mediterranean Anemia. The company plans to apply for the R&D of investigational new drug (IND) of ß-Mediterranean Anemia, and gene therapy drugs mediated including RDEB and Adeno-Associated Virus (AAV) vectors. In June 2025, Zhongji Zhiyao (Nanjing) Biotechnology Co., Ltd. raised Series B funding from new investors Botong Venture Capital and Zhuhai Hengqin Kangyuan Huiying Investment Management Co., Ltd..

## Funding rounds

- Series A, Feb 1, 2022, $17M — Puhua Capital, Zhuhai Longmen Capital Management, Oceanpine Capital, Ennovation Ventures

## Investors

- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series A
- Zhuhai Longmen Capital Management (https://capitalatlas.ai/funds/zhuhai-longmen-capital-management) — Series A
- Oceanpine Capital (https://capitalatlas.ai/funds/oceanpine-capital) — Series A
- Ennovation Ventures (https://capitalatlas.ai/funds/ennovation-ventures) — Series A